ReviewEye and brain2025
Diagnostic and Management Strategies of Visual Snow Syndrome: Current Perspectives.
Review in Eye and brain, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Visual snow syndrome as a neuropsychiatric network disorder: clinical features, mechanisms, and therapeutic perspectives.Journal of neurology · 2026Review
- Learnings from familial visual snow syndrome: A case series.Headache · 2026Article
- An Overview of the Therapeutic Applications of Tinted Lenses Spectacles.Korean journal of ophthalmology : KJO · 2025Review
- Visual Snow Syndrome: Therapeutic Implications.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Visual Snow Syndrome (VSS) is characterized by the presence of dynamic, continuous, tiny dots in the entire visual field persisting for more than three months, with at least two associated symptoms- palinopsia, photopsia, photophobia, or nyctalopia. VSS was introduced as perpetual visual disturbance representing TV static, based on early case reports from 1995. Despite its recognition, VSS management remains vague as many cases are refractory to treatment. This literature review aims to provide a summary of all attempted treatments and efficacies to help physicians manage VSS. Methods: The authors performed a search of articles, literature reviews, and case reports using PubMed and Google Scholar with the key words "visual snow" and "treatment". Forty-one publications were identified; however, 14 were excluded as they did not discuss treatment options or focused on medical conditions associated with visual snow, such as migraine with aura. 27 articles were found to be relevant (from 1999-2024) with treatments in patients officially diagnosed with VSS. Treatments included pharmacotherapy, tinted lenses, neuromodulation, and behavioral therapy. Results: Based on this review of 27 publications, benzodiazepines and lamotrigine had the best effect (71.4% and 61.5% of patients had an improvement of VS symptoms on each medication, respectively). Antidepressants and AV nodal blocking agents were frequently prescribed but were less effective. VS symptoms improved with filtered lenses combined with cognitive behavioral therapy. Most treatments only partially alleviate VSS or manage associated symptoms like headache and palinopsia, rather than the visual snow itself. Conclusion: The subjective nature of VSS has posed challenges. Among pharmacological treatments, benzodiazepines and lamotrigine have the most favorable therapeutic ratio in managing VSS. FL-41 tinted lenses consistently provide symptom relief, with cognitive behavioral therapy showing promise as an emerging intervention. Due to the small sample size, further research is recommended to enhance the applicability of findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.